NZ237176A - Insulin cobalt iii complex compositions - Google Patents

Insulin cobalt iii complex compositions

Info

Publication number
NZ237176A
NZ237176A NZ237176A NZ23717691A NZ237176A NZ 237176 A NZ237176 A NZ 237176A NZ 237176 A NZ237176 A NZ 237176A NZ 23717691 A NZ23717691 A NZ 23717691A NZ 237176 A NZ237176 A NZ 237176A
Authority
NZ
New Zealand
Prior art keywords
insulin
iii
ins
pharmaceutical composition
composition according
Prior art date
Application number
NZ237176A
Other languages
English (en)
Inventor
Jorgen Frederick Hansen
Ulla Ribel-Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NZ237176A publication Critical patent/NZ237176A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
  • Medicinal Preparation (AREA)
NZ237176A 1990-02-21 1991-02-20 Insulin cobalt iii complex compositions NZ237176A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK045590A DK45590D0 (cg-RX-API-DMAC10.html) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
NZ237176A true NZ237176A (en) 1991-12-23

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ237176A NZ237176A (en) 1990-02-21 1991-02-20 Insulin cobalt iii complex compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (cg-RX-API-DMAC10.html)
JP (1) JPH05503940A (cg-RX-API-DMAC10.html)
AU (1) AU641991B2 (cg-RX-API-DMAC10.html)
CA (1) CA2075982A1 (cg-RX-API-DMAC10.html)
DE (1) DE69100626D1 (cg-RX-API-DMAC10.html)
DK (1) DK45590D0 (cg-RX-API-DMAC10.html)
HU (1) HUT63858A (cg-RX-API-DMAC10.html)
IE (1) IE910579A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ237176A (cg-RX-API-DMAC10.html)
PT (1) PT96841A (cg-RX-API-DMAC10.html)
WO (1) WO1991012817A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA911279B (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
RO112873B1 (ro) * 1993-09-17 1998-01-30 Novo Nordisk As Derivati de insulina
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
CN101955527B (zh) 2003-08-05 2016-04-20 诺沃挪第克公司 新型胰岛素衍生物
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
AU2007298919C1 (en) 2006-09-22 2014-02-06 Novo Nordisk A/S Protease resistant insulin analogues
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
RS57004B1 (sr) 2013-10-07 2018-05-31 Novo Nordisk As Novi derivat analoga insulina
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
CA2075982A1 (en) 1991-08-22
HUT63858A (en) 1993-10-28
WO1991012817A1 (en) 1991-09-05
EP0516704B1 (en) 1993-11-10
JPH05503940A (ja) 1993-06-24
PT96841A (pt) 1991-11-29
IE910579A1 (en) 1991-08-28
AU7337891A (en) 1991-09-18
EP0516704A1 (en) 1992-12-09
ZA911279B (en) 1991-10-30
DE69100626D1 (de) 1993-12-16
DK45590D0 (cg-RX-API-DMAC10.html) 1990-02-21
HU9202721D0 (en) 1992-12-28
AU641991B2 (en) 1993-10-07

Similar Documents

Publication Publication Date Title
NZ237176A (en) Insulin cobalt iii complex compositions
US5266333A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
DE3880346T2 (de) Insulinderivate.
DE69425464T2 (de) Polysaccharidderivat und wirkstoffträger
DE69722397T2 (de) Insulin-derivate und ihre verwendung
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
Zhang et al. Polymer–covalent organic frameworks composites for glucose and PH dual‐responsive insulin delivery in mice
EP3554534B1 (en) Insulin containing pharmaceutical compositions
EP0646379A1 (en) Insulin formulation
WO1995005848A1 (en) Protracted glp-1
IE61340B1 (en) Stable interferon complexes
JPH10511365A (ja) 遅延性glp−1組成物
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
CN109069590A (zh) 包含聚山梨酯80的胰岛素制剂
EP0119650A2 (en) Galactosyl-insulin conjugates useful in treating diabetics
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
CS114290A3 (en) Specifically glycosylated insulin derivatives
ZA200600846B (en) Novel insulin derivatives
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
CA2463769A1 (en) Composition and method for treating diabetes
KR20110014564A (ko) 이중-가닥 폴리에틸렌 글리콜-수식된 성장 호르몬, 이의 제조 방법 및 용도
TW201934137A (zh) 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
DE2646223C2 (cg-RX-API-DMAC10.html)